Catalyst ligands

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(Cmpd 12): 4,7-Diphenyl-2-(3-pyridyl)-1,10-phenanthroline. n-Butyllithium (18.8 ml of a 1.6 M solution in hexane, 0.03 mol) is added under argon to a cold (-78C) tetrahydrofurane (100 ml). 3-bromopyridine (4.75 g, 0.03 mol) is then added during 15 minutes while keeping the temperature at -78C. The brown solution is stirred 50 minutes at -78C, thereafter finely powdered 4,7-diphenyl-1,10-phenanthroline (6.64g, 0.02 mol) is added and the mixture is allowed to warm to room temperature during 40 minutes. Methanol (30 ml) is then added and the brown solution is evaporated on a rotary evaporator. The residue is dissolved in dichloromethane (300 ml) and methanol (10 ml), manganese dioxide (30 g) is added and the mixture is stirred at room temperature 12 h. The solids are removed by filtration, the filtrate is evaporated and the residue is crystallized from dichloromethane-ethanol and then o-dichlorobenzene to afford 2.1 g of the title compound. Light yellow, microcrystalline powder, mp (DSC in air, scan rate 10Cmin-1) = 268.3-273.5C. 1H-NMR (300 MHz, CD3Cl): 9.46 (d, J=1.8 Hz, 1H), 9.31 (d, J=4.5 Hz, 1H), 8.86 (d, J=11.7 Hz, 1H), 8.73 (d, J=6.6 Hz, 1H), 8.08 (s, 1H), 7.89 (s, 2H), 7.64-7.48 (m, 12H). MS for C29H19N3 (409.49) found M=409.69.

1662-01-7, 1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BASF SE; EP2161272; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of a tetrabutylammonium salt of (2S,5R)-N-{[1-tert-butoxycarbonyl (2R, 4S)-4-(morpholin-4-yl)pyrrolidin-2-ylj methoxy } -6-hydroxy-7-oxo- 1,6- diazabicyclo[3.2.ljoctane-2-carboxamide (1.5 g, 0.0032 mol) in dimethylformamide (15 ml) was added sulfur trioxide: dimethylformamide complex (1.0 g, 0.0064 mol) under stirring at temperature of about 0 C. The reaction mixture was stirred at 0 C for 10 minutes and then allowed to warm to 25C. After 1 hr of stirring a solution of tetra butyl ammonium acetate (2.89 g, 0.0096 mol) in water (8 ml) was added to the reaction mixture under continuous stirring. After completion of 1 hr stirring the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The residue obtained was then purified by silica gel(60-120 mesh size) column chromatography using 6% Methanol: DCM mixture as an eluant to get required compound. The solvent of the combined fractions were evaporated to provide 1.2 g of the titled compound as white solid, 47% yield. Analysis:Mass: 548.4 (M-1) as free acid; for Molecular weight: 791.07 and Molecular formula:C37H70N60 ftS?H NMR (CDC13, 400 MHz): 5 10.42 (brs, 1H), 4.38-4.28 (m, 1H), 3.98-3.92 (m, 1H), 3.86- 3.68 (m, 5H), 3.62-3.52 (m, 1H), 3.42-3.20 (m, 1OH), 2.98-2.84 (m, 2H), 2.58-2.32 (m, 5H), 2.24-2.14 (m, 1H), 1.96-1.84 (m, 2H), 1.84-1.62 (m, 12H), 1.56-1.42 (m, 17H), 1.06-0.97 (m, 12H).

10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar Jagdishwar; SHENGULE, Sudhir; PAWAR, Mangesh; BHUNIYA, Rajib; MUNSHI, Zaki Ahmed Burhanuddin; JOSHI, Prashant Ratnakar; TAKALKAR, Swapna Shripad; PATEL, Mahesh Vithalbhai; (64 pag.)WO2017/98425; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of a tetrabutylammonium salt of (2S,5R)-N-{[1-tert-butoxycarbonyl (2R, 4S)-4-(morpholin-4-yl)pyrrolidin-2-ylj methoxy } -6-hydroxy-7-oxo- 1,6- diazabicyclo[3.2.ljoctane-2-carboxamide (1.5 g, 0.0032 mol) in dimethylformamide (15 ml) was added sulfur trioxide: dimethylformamide complex (1.0 g, 0.0064 mol) under stirring at temperature of about 0 C. The reaction mixture was stirred at 0 C for 10 minutes and then allowed to warm to 25C. After 1 hr of stirring a solution of tetra butyl ammonium acetate (2.89 g, 0.0096 mol) in water (8 ml) was added to the reaction mixture under continuous stirring. After completion of 1 hr stirring the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The residue obtained was then purified by silica gel(60-120 mesh size) column chromatography using 6% Methanol: DCM mixture as an eluant to get required compound. The solvent of the combined fractions were evaporated to provide 1.2 g of the titled compound as white solid, 47% yield. Analysis:Mass: 548.4 (M-1) as free acid; for Molecular weight: 791.07 and Molecular formula:C37H70N60 ftS?H NMR (CDC13, 400 MHz): 5 10.42 (brs, 1H), 4.38-4.28 (m, 1H), 3.98-3.92 (m, 1H), 3.86- 3.68 (m, 5H), 3.62-3.52 (m, 1H), 3.42-3.20 (m, 1OH), 2.98-2.84 (m, 2H), 2.58-2.32 (m, 5H), 2.24-2.14 (m, 1H), 1.96-1.84 (m, 2H), 1.84-1.62 (m, 12H), 1.56-1.42 (m, 17H), 1.06-0.97 (m, 12H).

10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar Jagdishwar; SHENGULE, Sudhir; PAWAR, Mangesh; BHUNIYA, Rajib; MUNSHI, Zaki Ahmed Burhanuddin; JOSHI, Prashant Ratnakar; TAKALKAR, Swapna Shripad; PATEL, Mahesh Vithalbhai; (64 pag.)WO2017/98425; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of (-)-cinchonidine (1.0 mmol) and benzyl bromide 3 (1.0 mmol) having sulfonamidegroup was stirred in DMF (4 mL) at 25 C for 20 h. After the reaction was completed, the reaction mixture was added dropwise to ether (50mL) with stirring. The solid precipitated was filtered,washed with ether (20 mL) and hexane (20 mL) to afford cinchonidinium salt 5

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Itsuno, Shinichi; Yamamoto, Shunya; Takata, Shohei; Tetrahedron Letters; vol. 55; 44; (2014); p. 6117 – 6120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.194800-56-1,[2,2′-Bipyridine]-4,4′-diyldiphosphonic acid,as a common compound, the synthetic route is as follows.

Dichloro-p-cymene ruthenium dimer (0.200 g, 0.320 mmol, 1.00 equiv.) was dissolved in degassed, dry DMF (122 mL). 4,4?-Bis(5-hexylthiophene-2-yl)-2,2?-bipyridin (0.310 g, 0.640 mmol, 2.00 equiv.) was added and the mixture was first stirred at 80 C for 4 h and then at room temperature for 12 h. Afterwards, dpbpy 7 (0.200 g, 0.640 mmol) was added and the reaction mixture stirred at 150 C for 4,5 h. After cooling to room temperature an excess of ammonium thiocyanate (2.02 g, 26.5 mol) was added, the mixture heated to 150 C and stirred for 4 h and then at room temperature for 12 h. The solvent was removed in vacuo, the crude product was precipitated with water, and subsequently purified by size exclusion chromatography on a Sephadex-LH 20 column. The desired complex was obtained as dark-red crystals (180.0 mg, 0.176 mmol, 27 %). 1H NMR (700 MHz, CD3OD): delta in ppm 8.96-8.92 (m, 2H), 8.83 (s, 1H), 8.13 (bs, 1H), 7.82 (d, J= 3.7, 1H), 7.74-7.73 (m, 1H), 7.70-7.62 (m, 4H), 7.54 (d, J= 6.3 Hz, 1H), 7.46 (dd, J= 6.0, 2.1 Hz, 1H), 7.37-7.335 (m, 1H). 7.17 (d, J= 5.8 Hz, 1H), 6.91 (d, J= 3.9, 1H), 2.86 (t, J= 7.6 Hz, 4H), 1.72 (p, J= 7.6 Hz, 4H), 1.42-1.31 (m, 12H), 0.90 (t, J= 7.0 Hz, 6H). 31P NMR (400 MHz; MeOD-d4): delta in ppm= 6.88 (s). HRMS (ESI) m/z: [M-2H]-2: calcd. for (C42H44N6O6S4P2Ru-2): 510.0367; found 510.0364. Anal. Calcd for RuC42H46N6O6P2S4: H, 4.54; C, 49.35; N, 8.22. Found: H, 5.01; C, 36.26; N, 5.64. IR (max, solid): 2921 nu(CH3), 2850 nu(H-O-P=O), 2096 nu(SCN), 1273 nu(NSC).

194800-56-1, The synthetic route of 194800-56-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Neuthe, Katja; Bittner, Florian; Stiemke, Frank; Ziem, Benjamin; Du, Juan; Zellner, Monika; Wark, Michael; Schubert, Thomas; Haag, Rainer; Dyes and Pigments; vol. 104; (2014); p. 24 – 33;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

23616-79-7, N-Benzyl-N,N-dibutylbutan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

b N-{5-(4-Chlorophenyl)pent-1-en-4-yl}-N-ethoxymethyl-3,5-dimethylbenzamide 2.36 ml (25.2 mmol) of chloromethyl ethyl ether are added in small portions over the course of 2 hours to a vigorously stirred solution of 5.5 g (16.8 mmol) of N-{5-(4-chlorophenyl)pent-1-en-4-yl}-3.5-dimethylbenzamide and 100 mg of benzyltributylammonium chloride in 15 ml of 50% strength aqueous sodium hydroxide solution and 15 ml of dichloromethane at 0-50. The organic phase is taken up in dichloromethane and water, the organic phase is separated off, dried over sodium sulfate and evaporated to dryness under reduced pressure. The oily residue is purified by chromatography on silica gel with ethyl acetate/hexane (1:4) as mobile phase; TLC (ethyl acetate/hexane; 1:3): Rf =0.50; 1H-NMR (300 MHz, CDCl3): mixture of rotamers, delta=7.31-7.18 (m, 4H), 7.04-6.85 (m, 2.6H), 6.42 (br. s, 0.4H), 5.92-5.60 (m, 1H), 5.20-5.02 (m, 2H), 4.54-4.24 (m, 2H), 3.96-3.67 (m, 1H), 3.25-2.40 (m, 6H), 2.28 (s, ca 5H), 2.24 (s, ca 1H), 1.34-1.21 (m, ca 0.5H), 1.08 (t, J=7, ca 2.5 H).

23616-79-7, 23616-79-7 N-Benzyl-N,N-dibutylbutan-1-aminium chloride 159952, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Ciba-Geigy Corp.; US5310743; (1994); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of (CBT)2Ir(m-Cl)2Ir(CBT)2 (0.84 g, 0.40 mmol) and1,10-phenanthroline (phen, 0.17 g, 0.84 mmol) in glycol (30 mL)wasstirred at 150 C in argon for 16 h. After being cooled to room temperature,an orange-red solution was obtained, and then 10 mLaqueous solution ofNH4PF6 (0.4 mol L1)was added in. The resultantorange floccules were filtered, washed withwater and then dried invacuum. The pure product was obtained by silica gel column chromatography,eluting with a mixture of CH2Cl2 and acetonitrile (10:1,volume ratio). Yield 90.3% (0.97 g, 0.72 mmol)

4733-39-5, The synthetic route of 4733-39-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Tang, Huaijun; Chen, Zeyu; Wei, Liying; Miao, Jingsheng; Meng, Guoyun; He, Yonghui; Wu, Hongbin; Dyes and Pigments; vol. 131; (2016); p. 340 – 348;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.943757-71-9,(R)-2-(Diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine,as a common compound, the synthetic route is as follows.

943757-71-9, To a solution of trans-cinnamaldehyde (134.2 g, 1.015 mol) in methanol (2 L), (2R)-2-[diphenyl[(trimethylsilyl)oxy]methyl]pyrrolidine (16.5 g, 50.6 mmol), nitroethanol (138.8 g, 1.524 mol), and benzoic acid (12.4 g, 101.5 mmol) were added, and the mixture was stirred at room temperature for 3 days under nitrogen atmosphere. Sodium bicarbonate (424.2 g, 5.05 mol) was added thereto, and the mixture was further stirred for 12 hours. The reaction solution was concentrated under reduced pressure, distilled water was added thereto, followed by extraction with ethyl acetate. The obtained organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. After the residue was dissolved in a mixed solvent of ethyl acetate and hexane (1:1) under heating at 80C, the reaction solution was stirred and gradually cooled to room temperature. After 3 hours, the precipitated solid was filtered out to obtain (4R,5R)-4-phenyl-5-nitrotetrahydro-2H-pyran-2-ol (128.68 g, 0.576 mol, >99%ee).

943757-71-9 (R)-2-(Diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine 16218310, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Sumitomo Dainippon Pharma Co., Ltd.; IKUMA Yohei; FUKUDA Nobuhisa; IWATA Masato; KIMURA Hidenori; SUZUKI Kuniko; EP2876105; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13040-77-2,6-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

The reaction was performed under argon. Substituted azole (excess) and potassium tert-butoxide were dissolved at RT in dry and degassed DMSO. An exothermic reaction occurred. The mixture was stirred for 10 min to allow the reaction to finish and cool. Then, a substituted halopyridine was added. The reaction mixture was stirred for 24 h at 140C to give a suspension. It was cooled to RT. Water (50mL) was added: the product precipitated on stirring/sonication. The solid was filtered, washed with water, and extracted with dichloromethane and water. The organic layer was washed with water to extract DMSO. Purification by chromatography on silica (20g) removed the starting materials and by-products on elution with 0-0.4% CH3OH in CH2Cl2, and provided the pure product on elution with 0.4-1.0% CH3OH in CH2Cl2. Anal. Calc. for C14H12N4 (MW 236.27): C, 71.17; H, 5.12; N, 23.71. Found: C, 71.44; H, 5.10; N, 24.05%., 13040-77-2

The synthetic route of 13040-77-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Shavaleev, Nail M.; Kessler, Florian; Graetzel, Michael; Nazeeruddin, Mohammad K.; Inorganica Chimica Acta; vol. 407; (2013); p. 261 – 268;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13104-56-8,4′-(4-Methoxyphenyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.

Co(NO3)2*6H2O (67 mg, 0.24 mmol), meophtpy (78 mg, 0.23 mmol), and NaClO4 (67.2 mg, 48 mmol) were dissolved in 30 ml of CH3CN. A few drops of water were added until the solution became clear. A crop of purple crystals was obtained in two weeks., 13104-56-8

As the paragraph descriping shows that 13104-56-8 is playing an increasingly important role.

Reference£º
Article; Fu; Shu; Luo; Tang; Li; Liu; Cheng; Wang; Liu; Journal of Structural Chemistry; vol. 59; 2; (2018); p. 398 – 410; Zh. Strukt. Khim.; vol. 59; 2; (2018); p. 412 – 424,13;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI